Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, provides insights from the Phase I/II BRUIN study (NCT03740529), focusing on the subgroup of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with the non-covalent BTK inhibitor pirtobrutinib. The overall response rate (ORR) in this patient population was 50%, with a median progression-free survival (PFS) between 5 and 6 months. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть